- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04176081
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer (SChLAP/IDC)
A Prospective, Randomized, Open-label, Multi-centre, Phase II Trial Evaluating IDC/SChLAP1 as a Biomarker for Prediction of Response to Intensified Combined Modality Treatment
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as Intermediate-Risk PCa (IR-PCa).
The standard treatment for IR-PCa is radiation therapy (RT) with or without hormone therapy which can result in cure in some men. In other men, the cancer can come back or spread to other areas of the body. Treatment response in men with IR-PCa is highly variable. This uncertainty has led to significant under- and over-treatment.
This study aims to find out if the addition of intensive treatment (hormonal therapy: darolutamide + degarelix) to standard treatment for PCa will work better than standard treatment alone. To do this, some participants will receive hormone therapy and others will not. All participants will receive RT.
Currently, it is difficult to identify men who may require more intensive therapy. Current methods, such as using prostate specific antigen (PSA) alone, may not give the doctor enough information about who requires more intensive treatment. The researchers conducting this study believe that a particular arrangement of cancer cells [called intraductal carcinoma (IDC)] and the presence of a genetic marker called SChLAP1 can be used to identify people who would benefit from more intensive therapy.
Hormonal therapy such as with drugs called darolutamide (new drug for PCa) and Degarelix, reduce androgens (male hormones, such as testosterone) or block their effect on the cells. PCa cells require androgens to grow and divide, so removal of androgens may be effective in preventing the return of cancer following radiation therapy.
Although darolutamide has been studied in about 1000 men with PCa and seems promising and well tolerated it is considered an experimental drug, therefore it can only be used in a research study such as this one. Degarelix has been approved by Health Canada to treat PCa.
This is a phase 2, open label, randomized, controlled study and will be conducted across sites in Canada. To qualify, men must have IR-PCa and have both SChLAP1 and IDC present or both absent. Participants will be randomized to receive RT with hormone therapy or RT only. The study treatment period is 6 months for the RT + hormone therapy group. RT will take about 1-2 weeks. All participants will be followed for 5 years with multiple visits to assess safety and treatment effects.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sunakshi Chowdhary
- Phone Number: 5836 416-946-4501
- Email: Sunakshi.Chowdhary@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- UHN Princess Margaret Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male ≥ 18 years of age;
- Pathologic (histologic) proven diagnosis of prostate adenocarcinoma within 180 days prior to consent;
- PSA measurement performed within 60 days prior to consent;
- IR-PCa as per National Comprehensive Cancer Network (NCCN) criteria (PSA >10 and < 20 ng/mL and/or Gleason score 7 and/or T-category T2b-T2c clinical or ultrasound);
- UIR-PCa, at least one of the following:
- 2 or 3 NCCN IR-PCa criteria;
- Gleason score 4+3;
- >50% diagnostic cores involved by adenocarcinoma;
- Clinically negative (N0) stage, as defined by pelvic-CT or pelvic-MRI within 4 months prior to consent;
- No evidence of bone metastases (M0) assessed by a bone scan within 4 months prior to consent;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
- Able and willing to provide signed informed consent as per International Conference on Harmonization - Good Clinical Practices Guidelines (ICH-GCP) and applicable regulations.
Exclusion Criteria:
- Received any form of hormonal therapy such as bilateral orchiectomy, LHRH agonist/antagonist (e.g. goserelin, leuprolide, degarelix, etc.), anti-androgens (e.g. flutamide, bicalutamide, etc.), 5α-reductase inhibitors (e.g. finasteride, dutasteride, etc.) and/or estrogens within 1 year of consent;
- Received prior cytotoxic therapy for prostate cancer (e.g. taxanes, mitoxantrone);
- Currently taking medications that might cause toxicity if combined with darolutamide (see section 4.6);
- Hemoglobin < 9.0 g/dL, independent of transfusion and/or growth factors, measured within 90 days prior to consent;
- Platelet count < 100,000 × 109/μL, independent of transfusion and/or growth factors, within 90 days prior to consent;
- Serum albumin < 3.0 g/dL within 90 days prior to consent;
- Abnormal renal function, assessed within 90 days prior to consent:
- Creatinine > 2mg/dL;
- Glomerular filtration rate (GFR) ≤ 35 mL/min, estimated by Cockcroft-Gault formula or measured directly by 24 hour urine.
- Abnormal liver function assessed within 90 days prior to consent:
- Total bilirubin > 1.5 times the upper limit of normal range;
- Aminotransferases (ALT or AST) >1.5 times the upper limit of normal range;
- Currently on anticoagulant therapy for any indication (e.g. atrial fibrillation, valve replacement, pulmonary embolism, etc.);
- Any cardiac events (e.g. unstable angina, myocardial infarction and/or congestive heart failure;
- Does not agree to use highly effective method of birth control if he is having sex with a woman of childbearing potential or does not agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 4 weeks following the last dose of study drug;
- Known hypersensitivity (or known allergic reaction) to the study treatment(s) or any of its ingredients (as listed in Investigator's brochure);
- Planned initiation of alternative therapy for prostate cancer or investigational therapy;
- Participation in another interventional clinical trial during and / or within 3 months of consent for this study;
- Subject was previously randomized in this trial;
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 1: Radiation Therapy Only
Participants randomized to Group 1 will receive radiation therapy only.
|
The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx.
The study will not include elective nodal irradiation.
Every fraction will have 3D image guidance (i.e.
cone-beam CT).
|
Experimental: Group 2: Radiation Therapy + darolutamide + degarelix
Participants randomized to Group 2 will receive radiation therapy only + darolutamide + degarelix.
|
The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx.
The study will not include elective nodal irradiation.
Every fraction will have 3D image guidance (i.e.
cone-beam CT).
Darolutamide will be administered orally as a tablet.
Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
Other Names:
Degarelix is administered by subcutaneous injection.
The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence Free Survival
Time Frame: Recurrence Free Survival will be monitored for a duration of 5 years.
|
Recurrence Free Survival (RFS), with recurrence event defined as (whichever occurs first):
|
Recurrence Free Survival will be monitored for a duration of 5 years.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in RFS rates (as defined in primary outcome measure) between IDC/SChLAP1 and treatment groups.
Time Frame: 5 years
|
To prospectively assess the role of IDC/SChLAP1 in UIR-PCa treated with curative intent radiation to predict those who derive the greatest benefit from ST-2gen-ADT.
|
5 years
|
Incidence of early biochemical failure as defined by Pheonix criteria (i.e., within first 2 years of follow-up; surrogate of lethal disease).
Time Frame: 5 years
|
To determine the impact of ADT hormone therapy combined with radiation therapy compared to radiation therapy alone in improving rates of early failures.
|
5 years
|
Rates of positive prostate biopsies (local failure) performed at time of recurrence as per standard of care.
Time Frame: 5 years
|
To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.
|
5 years
|
Testosterone levels
Time Frame: 5 years
|
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on the duration of castrate testosterone levels (<50 ng/dL) after treatment completion.
|
5 years
|
Changes in prostate cancer-specific HRQoL as measured by abbreviated EPIC (urinary, bowel, sexual, and hormonal domains) questionnaire, as a function of treatment assignment
Time Frame: 5 years
|
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).
|
5 years
|
Rate of maximal biochemical control, defined as 2 consecutive undetectable PSA (<0.05 ng/mL) during follow-up.
Time Frame: 5 years
|
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on PSA levels.
|
5 years
|
Rates of positive molecular imaging results (local, regional and/or distant failure) performed at time of recurrence as per standard of care.
Time Frame: 5 years
|
To assess the patterns of failure after ST-2gen-ADT combined with SABR compared to SABR alone.
|
5 years
|
Changes in prostate cancer-specific HRQoL as measured by SF-12 questionnaire, as a function of treatment assignment
Time Frame: 5 years
|
To determine the effect of ST-2gen-ADT combined with SABR compared to SABR alone on Health Related Quality of Life (HRQOL).
|
5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent Adverse Events
Time Frame: 5 years
|
To determine the safety of ST-2gen-ADT combined with SABR compared to SABR alone.
|
5 years
|
Tolerability of Treatment
Time Frame: 5 years
|
To determine the tolerability of ST-2gen-ADT combined with SABR compared to SABR alone by determining the number of subjects discontinuing investigational products due to Adverse Events
|
5 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Neil Fleshner, MD, UHN Princess Margaret Cancer Centre
- Principal Investigator: Alejandro Berlin, MD, UHN Princess Margaret Cancer Centre
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SChLAP/IDC Study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Oropharyngeal HPV-Positive Squamous Cell CarcinomaUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina